All In Biotech

Drug Trial Radar · NCT07828002

The GranStone Trial

Prevention of Kidney Stones Due to Paraffin Oil Induced Granuloma: A Prospective Interventional Study

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Mar 2029

Study completion Apr 2029

Sponsor

Lead sponsor
Martin Blomberg JensenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Copenhagen University Hospital at Herlev
First posted
Sep 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate whether treatment with empagliflozin or losartan can reduce the risk of kidney stone formation in patients with paraffin disease, a condition caused by the injection of paraffin oil into muscle tissue for cosmetic muscle enlargement. Paraffin disease can lead to chronic inflammation, disturbances in calcium regulation, high blood calcium levels, kidney stones, and impaired kidney function. Previous studies from Herlev-Gentofte Hospital have shown that kidney stones occur in nearly half of affected patients, while approximately one-third develop reduced kidney function. Current treatment primarily consists of high-dose corticosteroids, which can reduce blood calcium levels but cause substantial adverse effects and may not adequately control the underlying disease process. Both empagliflozin and losartan are widely used medications with documented kidney-protective effects in other chronic kidney diseases. This randomized clinical trial will evaluate whether either treatment can prevent kidney stone formation and slow kidney-related complications in patients with paraffin disease. The purpose of this study is to determine whether treatment with empagliflozin or losartan can prevent kidney stone formation and improve kidney health in patients with paraffin disease.

Conditions

  • Paraffinoma
  • Granuloma, Foreign-Body

Interventions

  • empagliflozin (Jardiance) 25 mgDrug

    Once daily 25 mg tablet PO

  • Losartan 100 mgDrug

    Once daily 100 mg tablet PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Image verified new or increased nephrolithiasis or nephrocalcinosis (from 0-24 months).Time frame: From baseline to end of follow-up at 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Division of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital Herlev, Herlev

    Herlev, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.